Immutep Ltd
ASX:IMM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.27
0.4806
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Immutep Ltd
Immutep Ltd
Free Cash Flow
Immutep Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immutep Ltd
ASX:IMM
|
Free Cash Flow
-AU$35.4m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-9%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Free Cash Flow
-$48.7m
|
CAGR 3-Years
22%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Free Cash Flow
$1.5B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
33%
|
CAGR 10-Years
5%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Free Cash Flow
AU$31.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Free Cash Flow
AU$13.1m
|
CAGR 3-Years
100%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Free Cash Flow
-AU$38.9m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-28%
|
|
Immutep Ltd
Glance View
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.
See Also
What is Immutep Ltd's Free Cash Flow?
Free Cash Flow
-35.4m
AUD
Based on the financial report for Jun 30, 2024, Immutep Ltd's Free Cash Flow amounts to -35.4m AUD.
What is Immutep Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-9%
Over the last year, the Free Cash Flow growth was 0%. The average annual Free Cash Flow growth rates for Immutep Ltd have been -26% over the past three years , -18% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet
